Table 6.
Outcomes by risk score
| ENESTnd study arms | Low risk | Intermediate risk | High risk | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease progression, n (%) | PFS | OS | Disease progression, n (%) | PFS | OS | Disease progression, n (%) | PFS | OS | |
| Nilotinib 300 mg twice daily | 1 (1%) | 96.0% | 97.0% | 2 (2%) | 92.9% | 93.8% | 7 (9%) | 86.2% | 88.8% |
| Nilotinib 400 mg twice daily | 1 (1%) | 99.0% | 99.0% | 1 (1%) | 96.9% | 96.9% | 4 (5.1%) | 90.0% | 91.5% |
| Imatinib (400 mg) | 0 | 100.0% | 100.0% | 10 (9.9%) | 87.9% | 88.5% | 11 (14.1%) | 82.6% | 84.2% |
Estimated 5-year PFS and OS and progression to accelerated phase or blast phase on study for ENESTnd are shown. The ENESTnd data show that disease progression occurs more frequently in high-risk patients and that for nilotinib-treated intermediate- and high-risk patients, the risk of progression was lower with nilotinib than with imatinib.
Adapted with permission from National Comprehensive Cancer Network10. Guidelines® for Chronic Myeloid Leukemia V.1.2021. © 2021 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
OS, overall survival; PFS, progression-free survival.